Clinical Trial Update: Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tolerability of adjuvant cisplatin/docetaxel after complete resection of stage IB/II non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED